Compared with Chemoembolization, in the Treatment of Unresectable Hepatocellular Cancer

8%, P 5 0.003). Results: Actuarial survival was not significantly different between patients treated with 131I-lipiodol and patients treated with TACE/TAE. Survival at 6 mo, 1 y, 2 y, and 3 y was 86%, 69%, 54%, and 45%, respectively, after 131I-lipiodol, com- pared with 77%, 62%, 47%, and 43%, respectively, after TACE/ TAE. However, patients with PVT survived a mean of 454 d after 131I-lipiodol, compared with a mean of 171 d after TACE/TAE (P 5 0.025). In addition, patients with more advanced disease (Barcelona Clinic Liver Cancer stage D) lived on average 363 d after 131I-lipiodol, compared with 36 d after TACE/TAE (P 5 0.014). Conclusion: In patients with unresectable HCC, there was no difference in survival between 131I-lipiodol therapy and TACE/TAE treatment. However, in the patients with advanced clinical staging or PVT, there was a significant survival advan- tage for those treated with 131I-lipiodol.